Daniel Leung, MD
Vascular & Interventional Radiology · Newark, DENPI 1740375690
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $39,200 of the $57,502 with a category attached, or 68.2%. Boston Scientific accounts for 61.6% of it on its own, with 30 other manufacturers making up the rest. 2025 is the largest year on record at $24,102, more than ten times the $1,905 reported in 2019.
Across 286 payments — averaging $201.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$35K
- Cagent Vascular Inc$10K
- Shockwave Medical, Inc$4K
- Surmodics, Inc.$2K
- Penumbra, Inc.$2K
- Balt USA, LLC$1K
- plus $3K from 25 others
Across 190 payments — averaging $1459.12 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boston Scientific$128K
- Penumbra, Inc.$97K
- Inari Medical, Inc.$52K
What the payments were for
- Consulting fees$39,20068%
- Speaking & faculty fees$9252%
- Travel & lodging$5,0559%
- Food & beverage$12,32221%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 166 | $35,438 |
| Cagent Vascular Inc | 15 | $9,801 |
| Shockwave Medical, Inc | 11 | $3,741 |
| Surmodics, Inc. | 7 | $2,395 |
| Penumbra, Inc. | 15 | $1,724 |
| Balt USA, LLC | 16 | $1,451 |
| Vesalio, Inc. | 1 | $500 |
| Inari Medical, Inc. | 5 | $385 |
| Cook Medical LLC | 3 | $267 |
| Asahi Intecc USA, Inc. | 2 | $189 |
| Veryan Medical Incorporated | 3 | $181 |
| W. L. Gore & Associates, Inc. | 5 | $163 |
| Thrombolex, Inc. | 1 | $141 |
| Angiodynamics, Inc. | 1 | $138 |
| Johnson & Johnson | 8 | $125 |
| Sirtex Medical Inc | 6 | $100 |
| Medtronic | 3 | $99 |
| Triad Life Sciences Inc. | 1 | $97 |
| Siemens Medical Solutions USA, Inc. | 2 | $89 |
| GE HealthCare | 1 | $88 |
| Bard Peripheral Vascular, Inc. | 3 | $64 |
| Abbott | 2 | $48 |
| Imperative Care, Inc | 1 | $44 |
| Teleflex LLC | 1 | $44 |
| Okami Medical, Inc. | 1 | $41 |
| Galvanize Therapeutics, Inc | 1 | $35 |
| Cordis US CORP. | 1 | $32 |
| Smith+Nephew | 1 | $24 |
| Argon Medical Devices, Inc. | 1 | $21 |
| Guerbet LLC | 1 | $19 |
| Dova Pharmaceuticals | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL - THERAPIES$11,500
- Serrantor$9,600
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$3,575
- GENERAL THROMBECTOMY$3,158
- Pounce Venous Thrombectomy System$2,342
- Wolf Trap$1,560
- JETSTREAM SC$1,172
- WALLSTENT$1,000
- GENERAL CATHETERS$1,000
- ANGIOJET$1,000
- Indigo System$980
- GENERAL VASCULAR INTERVENTION$761
- Prestige Coil System$679
- Arterial Wolf$500
- ELUVIA$372
- Cook Medical Zilver PTX$262
- FlowTriever$200
- ClotTriever$200
- EKOSONIC$171
- Ranger$168
How this compares
Too few vascular & interventional radiology providers in Delawareto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 13 | $18,209 |
| ClopidogrelClopidogrel Bisulfate | 20 | $728 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $125 | $18,20913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few vascular & interventional radiology providers in Delawareon file to place this against a meaningful peer group, so we don't.
Other vascular & interventional radiology in Newark
- Christopher GrilliNewark$93K
- Assaf GraifNewark$83K
- Demetrios AgriantonisNewark$12K
- Henry SzetoNewark$10K
- Uchenna NwosuNewark$8K
- Helen PaikNewark$6K
- Johnpaul ChizeaNewark$4K
- Timothy NiesenNewark$1K
- Xavier MohammedNewark$946
- William HartzNewark$20
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.